Cantor Fitzgerald Predicts SPRY FY2026 Earnings

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of ARS Pharmaceuticals in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings per share of ($0.45) for the year. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its earnings results on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, hitting analysts’ consensus estimates of ($0.35). The business had revenue of $7.97 million during the quarter, compared to analysts’ expectations of $7.48 million.

SPRY has been the topic of a number of other research reports. William Blair reissued an “outperform” rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Wall Street Zen lowered shares of ARS Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Finally, Scotiabank started coverage on shares of ARS Pharmaceuticals in a report on Friday, March 7th. They issued a “sector outperform” rating and a $30.00 price target on the stock. One analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $31.00.

ARS Pharmaceuticals Stock Up 1.1%

Shares of NASDAQ:SPRY opened at $14.69 on Tuesday. The stock has a market cap of $1.44 billion, a PE ratio of -28.80 and a beta of 0.84. The company’s fifty day moving average is $14.02 and its 200 day moving average is $12.83. ARS Pharmaceuticals has a 52 week low of $7.55 and a 52 week high of $18.51.

Insider Activity

In related news, Director Brent L. Saunders sold 120,000 shares of the business’s stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $14.25, for a total transaction of $1,710,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Eric Karas sold 10,000 shares of the business’s stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $14.00, for a total transaction of $140,000.00. Following the sale, the insider now directly owns 7,696 shares in the company, valued at $107,744. The trade was a 56.51% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 332,971 shares of company stock valued at $4,621,888. Corporate insiders own 33.50% of the company’s stock.

Institutional Investors Weigh In On ARS Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC boosted its stake in ARS Pharmaceuticals by 93.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 344,171 shares of the company’s stock worth $3,631,000 after acquiring an additional 165,950 shares in the last quarter. Wells Fargo & Company MN boosted its stake in ARS Pharmaceuticals by 47.1% during the fourth quarter. Wells Fargo & Company MN now owns 41,701 shares of the company’s stock worth $440,000 after acquiring an additional 13,361 shares in the last quarter. Peregrine Capital Management LLC bought a new stake in ARS Pharmaceuticals during the fourth quarter worth about $4,469,000. Vanguard Group Inc. boosted its stake in ARS Pharmaceuticals by 3.5% during the fourth quarter. Vanguard Group Inc. now owns 3,464,952 shares of the company’s stock worth $36,555,000 after acquiring an additional 115,656 shares in the last quarter. Finally, MetLife Investment Management LLC boosted its stake in ARS Pharmaceuticals by 12.9% during the fourth quarter. MetLife Investment Management LLC now owns 33,086 shares of the company’s stock worth $349,000 after acquiring an additional 3,769 shares in the last quarter. Institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.